Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation

Xenobiotica

Volumn 26, Issue 7, 1996, Pages 765-778

  Rey Grobellet, X ^a   Eeckhoutte, C ^a   Sutra, J F ^a   Alvinerie, M ^a   Galtier, P ^a  

^a CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA NAPHTHOFLAVONE; CLOFIBRATE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ISOSAFROLE; PHENOBARBITAL; RIFAMPICIN; TIABENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME INDUCTION; LIVER MICROSOME; MALE; NONHUMAN; RABBIT;

EID: 0029680198     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046747     Document Type: Article

References (30)

1. AIX, L., REY-GROBELLET, X., LARRIEU, G., LESCA, P., and GALTIER, P., 1994, Thiabendazole is an inducer of cytochrome P4501A1 in cultured rabbit hepatocytes. Biochemical and Biophysical Research Communications, 202, 1483-1489.
2. ALVINERIE, M., SUTRA, J. F., and GALTIER, P., 1991, Dosage par CLHP de deux médicaments à caractère basique (triméthoprime, thiabendazole) à l'aide d'une phase greffée avec désactivation des silanols libres. Analusis, 19, 244-248.
3. BAUER, L. A., RAISYS, V. A., WATTS, M. T., and BALLINGER, J., 1982, The pharmacokinetics of thiabendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfusion. Journal of Clinical Pharmacology, 22, 276-280.
4. COCHIN, J., and AXELROD, J., 1959, Biochemical and pharmacological changes in the rat following chronic administration of morphine, nalorphine and normorphine. Journal of Pharmacology and Experimental Therapeutics, 125, 105-115.
5. COON, M. J., VAN DER HOEVEN, T. A., DAHL, S. B., and HAUGEN, D. A., 1978, Two forms of liver microsomal cytochrome P450, P450LM2 and P450LM4 (rabbit liver). Methods in Enzymology, 52, 109-117.
6. DALET BELUCHE, I., BOULENC, X., FABRE, G., MAUREL, P., and BONFILS, C., 1992, Purification of two cytochrome P450 isoenzymes related to CYP2A and CYP3A gene families from monkey liver microsomes. European Journal of Biochemistry, 204, 641-648.
7. DAUJAT, M., PICHARD, L., FABRE, I., PINEAU, T., FABRE, G., BONFILS, C., and MAUREL, P., 1991, Induction protocols for cytochrome P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods in Enzymology, 206, 345-353.
8. FRANZ, K. H., 1963, Clinical trials with thiabendazole against human strongyloidiasis. American Journal of Tropical Medicine and Hygiene, 12, 211-214.
9. FUJITANI, T., YONEYAMA, M., OGATA, A., UETA, T., MORI, K., and ICHIKAWA, H., 1991, New metabolites of thiabendazole and the metabolism of thiabendazole by mouse embryo in vivo and in vitro. Food and Chemical Toxicology, 29, 265-274.
10. GONZALEZ, F. J., 1992, Human cytochromes P450, Problems and prospects. Trends in Pharmacological Sciences, 13, 346-352.
11. HALPERT, J. R., GUENGERICH, F. P., BEND, J. R., and CORREIA, M. A., 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163-175.
12. KIKUTA, Y, KUSUNOSE, E., OKUMOTO, T., KUBOTA, I., and KUSUNOSE, M., 1990, Purification and characterization of two forms of cytochrome P450 with omega-hydroxylase activities towards prostaglandin A and fatty acids from rabbit liver microsomes. Journal of Biochemistry, 107, 280-286.
13. KUO, P. C., and ABE, K. Y., 1995, Cytokine-mediated production of nitric oxide in isolated rat hepatocytes is dependent on cytochrome P450III activity. FEBS Letters, 360, 10-14.
14. LAKE, B.J., 1987, Preparation and characterisation of microsomal fraction for studies on xenobiotic metabolism. In Biochemical Toxicology, edited by K. Snell and B. Mullock (Oxford: ICR), pp. 183-215.
15. LOWRY, O. H., ROSEBROUGH, W. J., FARR, A. L., and RANDALL, R. J., 1951, Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
16. LUBET, R. A., MAYER, R. T., CAMERON, J. W., NIMS, R. W., BURKE, M. D., WOFF, T., and GUENGERICH, F. P., 1985, Dealkylation of pentoxyresorufin : a rapid and sensitive assay for measuring induction of cytochrome(s) P450 by phenobarbital and other xenobiotics in the rat. Archives of Biochemistry and Biophysics, 238, 43-48.
17. MACKELLAR, Q. A., and SCOTT, E. W., 1990, The benzimidazole anthelminthic agents, a review. Journal of Veterinary Pharmacology and Therapeutics, 13, 223-247.
18. MIZUTANI, T., ITO, K., NOMURA, H., and NAKANISHI, K., 1990, Nephrotoxicity of thiabendazole in mice depleted of glutathione by treatment with DL-buthionine sulphoximine. Food and Chemical Toxicology, 28, 169-177.
19. MIZUTANI, T., YOSHIDA, K., and ITO, K., 1992, Nephrotoxicity of thiazoles structurally related to thiabendazole in mice depleted of glutathione by treatment with buthionine sulfoximine. Research Communications in Chemical and Pathological Pharmacology, 75, 29-38.
20. SALAÜN, J. P., SIMON, A., and DURST, F., 1986, Specific induction of lauric acid ω-hydroxylase by clofibrate, diethylhexyl-phtalate and 2,4-dichlorophenoxyacetic acid in higher plants. Lipids, 21, 776-779.
21. STONE, O. J., MULLINS, J. F., and WILLIS, C. J., 1965, Comparison of thiabendazole and 5 hydroxythiabendazole. Journal of Investigations in Dermatology, 45, 132-133.
22. TOCCO, D. J., EGERTON, J. R., BOWERS, W., CHRISTENSEN, V. W., and ROSENBLUM, C., 1965, Absorption, metabolism and elimination of thiabendazole in farm animals and a method for its estimation in biological materials. Journal of Pharmacological and Experimental Therapeutics, 149, 263-271.
23. TOCCO, D. J., ROSENBLUM, C., MARTIN, C. M., and ROBINSON, H. J., 1966, Absorption, metabolism, and excretion of thiabendazole in man and laboratory animals. Toxicology and Applied Pharmacology, 9, 31-39.
24. TOCCO, D. J., 1964, The metabolic fate of thiabendazole in Sheep. Journal of Medicinal Chemistry, 7, 399-405.
25. TOWBIN, H., STAEHFLIN, T., and GORDON, J., 1979, Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets, procedure and some applications. Proccedings of the National Academy of Sciences, USA, 76, 4350-4354.
26. TSUCHIYA, T., TANAKA, A., FUKUKOA, M., SATO, M., and YAMAHA, T., 1987, Metabolism of thiabendazole and teratogenic potential of its metabolites in pregnant mice. Chemical and Pharmaceutical Bulletin, 35, 2985-2993.
27. WILSON, C. G., PARKE, D. V., and CAWTHORNE, M. A., 1973, Investigation of 5-hydroxylation of thiabendazole in rat liver microsomal preparations. Biochemical Society Transactions, 1, 511-514.
28. WILSON, C. G., PARKE, D. V., GREEN, J., and CAWTHORNE, M. A., 1979, Inhibition of thiabendazole metabolism in the rat. Xenobiotica, 9, 343-351.
29. YAMAOKA, K., TANIGAWARA, K., NAKAGAWA, T., and UNO, T., 1981, A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobiodynamic, 4, 879-885.
30. YONEYAMA, M., and ICHIKAWA, H., 1986, Irreversible in vivo and in vitro binding of thiabendazole to tissue protein of pregnant mice. Food and Chemical Toxicology, 24, 1823-1826.